The Association Between Intravitreal Steroids and Post-Injection Endophthalmitis Rates

Overview

Journal Ophthalmology

Publisher Elsevier

Specialty Ophthalmology

Date 2015 Aug 19

PMID 26281823

Citations 38

Authors

Brian L VanderBeek

Sarah G Bonaffini

Liyuan Ma

Affiliations

Soon will be listed here.

Abstract

Purpose: To determine whether there is a difference in the risk of endophthalmitis after an intravitreal steroid injection compared with an anti-vascular endothelial growth factor (VEGF) agent injection.

Design: Retrospective cohort study.

Participants: A total of 75,249 beneficiaries in a large national US medical claims database representing 406 380 intravitreal injections.

Methods: Data were searched for all intravitreal injections (Current Procedural Terminology 67028) performed between 2003 and 2012. Cohorts were created on the basis of injections using anti-VEGF agents (bevacizumab, ranibizumab, aflibercept, and pegaptanib) and intraocular steroids (triamcinolone and dexamethasone). Endophthalmitis was defined as having a new endophthalmitis diagnosis (International Classification of Diseases 9th Revision 360.0x) and a "tap-and-inject" procedure (Current Procedural Terminology 67015, 67025), a vitrectomy (67036), or an intravitreal antibiotic injection on the same day, between 1 and 14 days post-injection. Exclusion occurred for any history of endophthalmitis, <6 months in the plan, or <1 month follow-up. The main outcome measure was the odds of endophthalmitis using logistic regression while controlling for injection-associated diagnosis, age, race, and gender.

Results: A total of 387,714 anti-VEGF injections and 18 666 steroid intravitreal injections were performed and followed by 73 (rate=0.019% or 1/5283 anti-VEGF injections) and 24 (rate=0.13% or 1/778 steroid injections) cases of endophthalmitis, respectively. After controlling for diagnosis, age, race, and gender, the odds ratio (OR) for endophthalmitis occurring was 6.92 (95% confidence interval, 3.54-13.52, P<0.001) times higher post-steroid injection compared with anti-VEGF injections.

Conclusions: The rate of endophthalmitis post-intravitreal steroid injection in a national cohort was 0.13% (1/778 injections). This rate conferred a significantly increased OR of 6.92 for endophthalmitis compared with anti-VEGF agents.

Citing Articles

Atypical Delayed-Onset Endophthalmitis Following Intravitreal Dexamethasone Implant Managed Without Implant Removal: A Rare Case Report and Literature Review.

Tripathi A, Rana V, Bandopadhyay S, Kaushik J, Kumar P Rom J Ophthalmol. 2025; 68(4):343-348.

PMID: 39936053 PMC: 11809834. DOI: 10.22336/rjo.2024.64.

[Implantable intravitreal corticosteroids in chronic noninfectious uveitis].

Kessler L, Albrecht M, Naujokaitis T, Auffarth G, Khoramnia R Ophthalmologie. 2024; 121(9):726-736.

PMID: 39145783 DOI: 10.1007/s00347-024-02096-4.

Endophthalmitis: a bibliometric study and visualization analysis from 1993 to 2023.

Fu X, Du W, Huang L, Ren X, Chen D Front Cell Infect Microbiol. 2024; 14:1355397.

PMID: 39081867 PMC: 11286575. DOI: 10.3389/fcimb.2024.1355397.

Impact of Prefilled Syringes and Masking on Postintravitreal Injection Endophthalmitis.

Louis A, Ali A, Patel S, Fan K, Rahman E, Pearce W J Vitreoretin Dis. 2023; 7(5):382-388.

PMID: 37706081 PMC: 10496810. DOI: 10.1177/24741264231191339.

The evolving therapeutic landscape of diabetic retinopathy.

Shughoury A, Bhatwadekar A, Jusufbegovic D, Hajrasouliha A, Ciulla T Expert Opin Biol Ther. 2023; 23(10):969-985.

PMID: 37578843 PMC: 10592121. DOI: 10.1080/14712598.2023.2247987.

References

Gillies M, Lim L, Campain A, Quin G, Salem W, Li J . A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014; 121(12):2473-81. DOI: 10.1016/j.ophtha.2014.07.002. View

Nentwich M, Yactayo-Miranda Y, Schwarzbach F, Wolf A, Kampik A, Mino de Kaspar H . Endophthalmitis after intravitreal injection: decreasing incidence and clinical outcome-8-year results from a tertiary ophthalmic referral center. Retina. 2013; 34(5):943-50. DOI: 10.1097/IAE.0000000000000011. View

Moshfeghi D, Kaiser P, Scott I, Sears J, Benz M, Sinesterra J . Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2003; 136(5):791-6. DOI: 10.1016/s0002-9394(03)00483-5. View

Lad E, Hammill B, Qualls L, Wang F, Cousins S, Curtis L . Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries. Am J Ophthalmol. 2014; 158(3):537-43.e2. DOI: 10.1016/j.ajo.2014.05.014. View

Cheung C, Wong A, Lui A, Kertes P, Devenyi R, Lam W . Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology. 2012; 119(8):1609-14. DOI: 10.1016/j.ophtha.2012.02.014. View

Nelson M, Tennant M, Sivalingam A, Regillo C, Belmont J, Martidis A . Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina. 2003; 23(5):686-91. DOI: 10.1097/00006982-200310000-00014. View

Francis J, Marr B, Brodie S, Gobin Y, Abramson D . Tethered vitreous seeds following intravitreal melphalan for retinoblastoma. JAMA Ophthalmol. 2014; 132(8):1024-5. DOI: 10.1001/jamaophthalmol.2014.436. View

Kiss S, Liu Y, Brown J, Holekamp N, Almony A, Campbell J . Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema. Clin Ophthalmol. 2014; 8:1611-21. PMC: 4155807. DOI: 10.2147/OPTH.S60893. View

Lee A, Akileswaran L, Tibbetts M, Garg S, Van Gelder R . Identification of torque teno virus in culture-negative endophthalmitis by representational deep DNA sequencing. Ophthalmology. 2014; 122(3):524-30. PMC: 4339625. DOI: 10.1016/j.ophtha.2014.09.001. View

10.

Tao Y, Jonas J . Intravitreal triamcinolone. Ophthalmologica. 2010; 225(1):1-20. DOI: 10.1159/000317909. View

11.

Bucher R, Hall E, Reed D, Richards J, Johnson M, Zacks D . Effect of intravitreal triamcinolone acetonide on susceptibility to experimental bacterial endophthalmitis and subsequent response to treatment. Arch Ophthalmol. 2005; 123(5):649-53. DOI: 10.1001/archopht.123.5.649. View

12.

Jonas J, Kreissig I, Spandau U, Harder B . Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am J Ophthalmol. 2006; 141(3):579-80. DOI: 10.1016/j.ajo.2005.10.007. View

13.

Holekamp N, Liu Y, Yeh W, Chia Y, Kiss S, Almony A . Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration. Am J Ophthalmol. 2014; 157(4):825-833.e1. DOI: 10.1016/j.ajo.2013.12.018. View

14.

Peyman G, Lad E, Moshfeghi D . Intravitreal injection of therapeutic agents. Retina. 2009; 29(7):875-912. DOI: 10.1097/IAE.0b013e3181a94f01. View

15.

Bhavsar A, Ip M, Glassman A . The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol. 2007; 144(3):454-6. PMC: 2065757. DOI: 10.1016/j.ajo.2007.04.011. View

16.

Nguyen Q, Ibrahim M, Watters A, Bittencourt M, Yohannan J, Sepah Y . Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. J Ophthalmic Inflamm Infect. 2013; 3(1):32. PMC: 3610181. DOI: 10.1186/1869-5760-3-32. View

17.

Westfall A, Osborn A, Kuhl D, Benz M, Mieler W, Holz E . Acute endophthalmitis incidence: intravitreal triamcinolone. Arch Ophthalmol. 2005; 123(8):1075-7. DOI: 10.1001/archopht.123.8.1075. View

18.

Khurana R, Palmer J, Porco T, Wieland M . Dexamethasone intravitreal implant for pseudophakic cystoid macular edema in patients with diabetes. Ophthalmic Surg Lasers Imaging Retina. 2015; 46(1):56-61. DOI: 10.3928/23258160-20150101-09. View